Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review

Background: The introduction of targeted therapies for the treatment of BRAF-mutant melanomas have improved survival rates in a significant proportion of patients. Nonetheless, the emergence of resistance to treatment remains inevitable in most patients. Scope of review: Here, we review known and emerging molecular mechanisms that underlay the development of resistance to MAPK inhibition in melanoma cells and the potential strategies to overcome these mechanisms. Major conclusions: Multiple genetic and non-genetic mechanisms contribute to treatment failure, commonly leading to the reactivation of the MAPK pathway. A variety of resistance mechanisms are enabled by the underlying heterogeneity and plasticity of melanoma cells. Moreover, it has become apparent that resistance to targeted therapy is underpinned by early functional adaptations involving the rewiring of cell states and metabolic pathways. General significance: The evidence presented suggest that the use of a combinatorial treatment approach would delay the emergence of resistance and improve patient outcomes.

Automated summary

The introduction of targeted therapies for BRAF-mutant melanomas has improved survival rates, but resistance to treatment remains inevitable, primarily due to multiple genetic and non-genetic mechanisms leading to treatment failure. The heterogeneity and plasticity of melanoma cells enable a variety of resistance mechanisms. Resistance to targeted therapy may be underpinned by early functional adaptations involving the rewiring of cell states and metabolic pathways.